Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and CEO, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and CEO, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston.
A live webcast will be available on the company’s Investors & News website at investors.passagebio.com, and a replay will be available for 90 days following the event.
Details
News Market Reaction – PASG
On Nov 5, the day this news came out, PASG closed 0.90% above the previous close.
Data tracked by StockTitan Argus for the Nov 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.
A live webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the event will be available for 90 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.